« Previous
Next »
Titles
- Paid family leave in the United States: a primer on working family trends and paid family leave1
- Part D plans generally include drugs commonly used by dual eligibles: 20201
- Partnering to create transportation options for families of children with special health care needs: San Joaquin County 5Cs1
- Pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval1
- Patient-focused drug development: collecting comprehensive and representative input : guidance for industry, Food and Drug Administration staff, and other stakeholders1
- Paying for value in behavioral health: what California can learn from other states' Medicaid programs1
- Payment and pricing decisions in health care reform: rate setting, cost control, and public option proposals1
- Payment reform1
- Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans1
- Peripheral vascular atherectomy devices: premarket notification [510(k)] submissions : guidance for industry and Food and Drug Administration staff1
- Pharmacist workforce and education in California1
- Pharmacy innovations to improve patient and family engagement: 10 ways hospitals help family caregivers prepare to manage medications1
- Physician workforce and medical education in California1
- Polarization and public health: partisan differences in social distancing during the coronavirus pandemic1
- Policies to achieve near-universal health insurance coverage1
- Policy for certain REMS requirements during the COVID-19 public health emergency: guidance for industry and health care professionals1
- Policy for coronavirus disease-2019 tests during the public health emergency (revised): immediately in effect guidance for clinical laboratories, commercial manufacturers, and Food and Drug Administration staff1
- Policy for the temporary use of portable cryogenic containers not in compliance with 21 CFR 211.94(e)(1) for oxygen and nitrogen during the COVID-19 public health emergency1
- Policy options for integrating care for individuals with both Medicare and Medicaid1
- Postmarketing adverse event reporting for medical products and dietary supplements during a pandemic1